Sequence: KFFKFFKFFK
PNA (dual antisense; 12-1 + 33-22)
| Experiment Id | EXP001063 |
|---|---|
| Paper | Identifying Antisense Oligonucleotides to Disrupt Small RNA Regulated Antibiotic Resistance via a Ce |
| Peptide | (KFF)3K |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 3 µM CPP-PNA 12-1 + 3 µM CPP-PNA 33-22 (final); also tested 4 µM each in reporter assay |
| Rna Concentration | 3 µM each (final) for MIC assays; 3–4 µM each (final) for reporter assay |
| Mixing Ratio | co-treatment (two CPP-PNAs at equal concentration) |
| Formulation Format | mixture of two CPP-PNA conjugates (each covalent); added directly to cultures |
| Formulation Components | CPP-PNA 12-1 (KFFKFFKFFK-O-aatgatgatagc) + CPP-PNA 33-22 (KFFKFFKFFK-O-atgacggtaata) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Escherichia coli MG1655 (liquid culture reporter assay and MIC assays) |
| Animal Model | |
| Administration Route | |
| Output Type | ompF-sfgfp reporter derepression; MIC (cephalothin, norfloxacin, nalidixic acid) |
| Output Value | Reporter derepression with 3–4 µM each; MIC reduced for cephalothin and nalidixic acid with 3 µM + 3 µM; norfloxacin MIC reduction not reproducible across replicates |
| Output Units | |
| Output Notes | Combination strategy synergistically increased antibiotic susceptibility by maintaining OmpF expression; authors specifically report consistent MIC reduction for nalidixic acid and cephalothin. |
| Toxicity Notes | High-dose control (8 µM scramble) affected growth and MIC; combination interpreted relative to 6 µM scramble control. |
| Curation Notes |